BioSpace News Archive

Will enable expedited development and review of ADP-A2M4 with the goal of commercialization in 2022 for patients with few other treatment options

Global digital therapeutics innovation leader, DarioHealth Corp. announced the launch of the Dario-powered digital diabetes program on Walmart.com.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced results from its latest proof of concept study

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received final U.S. Food and Drug Administration approval on its Abbreviated New Drug Application for a generic version of Carafate® (sucralfate) Oral Suspension, 1 g/10 ml.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that clinical data updates for cirmtuzumab, its investigational anti-ROR1 monoclonal antibody, will be presented at upcoming medical conferences.

Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced that new clinical data from its first-in-human study of ET019003, an anti-CD19 T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), will be presented in a poster session at the 61st American Society of Hematology (ASH) Annual Meeting on December 8, 2019.

Damage from concussion alters the way information is transmitted between the two halves of the brain, according to a new study presented at the annual meeting of the Radiological Society of North America.

IONTAS Limited announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells.

According to Coherent Market Insights, the global liquid chromatography mass spectrometry market is expected to be valued at US$ 3,683.7 million in 2019, and is expected to exhibit a CAGR of 12.0% over the forecast period.

MCRA, LLC is pleased to announce its role in the successful granting of a Breakthrough Device Designation for the CorFlow Therapeutics AG Controlled Flow Infusion System by the U.S. Food and Drug Administration.